Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165602 | 0.85 | — | — | |
| SCHEMBL10165638 | 0.85 | — | — | |
| SCHEMBL2673081 | 0.84 | MGLL (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2673084 | 0.84 | MGLL (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2673078 | 0.84 | MGLL (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2480029 | 0.81 | MGLL (0.41) | CYP3A4SMN1; SMN2 | |
| SCHEMBL10164616 | 0.81 | MGLL (0.41) | CYP3A4SMN1; SMN2 | |
| SCHEMBL10132910 | 0.78 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6742301 | 0.78 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10165559 | 0.77 | ALDH1A1 (0.37) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | ALDH1A1 2138/4885TP53 2995/4885CYP3A4 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.